Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED NA

Noninvasive Brain Stimulation for Mild Cognitive Impairment

NCT03331796 · View on ClinicalTrials.gov ↗

Study Summary

The goal of this study is to test the efficacy of repetitive Transcranial Magnetic Stimulation (rTMS) as a treatment for Mild Cognitive Impairment (MCI). Participants will be randomly assigned to one of three treatment groups: Group 1: Active Dorsolateral Prefrontal Cortex (DLPFC) rTMS; Group 2: Active Lateral Parietal Cortex (LPC) rTMS; and Group 3: Inactive rTMS (Placebo) control (evenly split between each coil location). Participation in the study takes approximately 7 ½ months-including a 2-to 4-week treatment phase (20 rTMS sessions) and a 6-month follow-up phase.

Interventions

  • DEVICE Active rTMS (Bilateral DLPFC)
  • DEVICE Active rTMS (Bilateral LPC)
  • DEVICE Placebo rTMS (Inactive)

Study Locations (1)

California

  • VA Palo Alto Health Care System — Palo Alto

Trial Details

FieldValue
Enrollment Target 69 participants
Start Date 2018-06-15
Est. Completion 2023-03-28
Phase NA

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03331796

The ClinicalTrials.gov registry entry for NCT03331796 describes a study currently listed as completed. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 69 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Palo Alto Veterans Institute for Research, which has 50 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 8 conditions, with Mild Cognitive Impairment appearing as the primary indexed condition, and to 3 interventions — of which Active rTMS (Bilateral DLPFC) is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT03331796 reports 1 study location spanning 1 distinct geographic area — top geographies include California. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT03331796 about?

NCT03331796 is a clinical study titled "Noninvasive Brain Stimulation for Mild Cognitive Impairment". The goal of this study is to test the efficacy of repetitive Transcranial Magnetic Stimulation (rTMS) as a treatment for Mild Cognitive Impairment (MCI). Participants will be randomly assigned to one of three treatment groups: Group 1: Active Dorsolateral Prefrontal Cortex (DLPFC) rTMS; Group 2: Act...

What is the current status of trial NCT03331796?

This trial is currently completed. It is a NA study. The enrollment target is 69 participants. The study started on 2018-06-15. Estimated completion is 2023-03-28.

What conditions does trial NCT03331796 study?

This clinical trial studies the following conditions: Mild Cognitive Impairment, Cognitive Decline, Cognitive Dysfunction, Memory Impairment, Memory Loss. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT03331796?

The interventions under investigation include: Active rTMS (Bilateral DLPFC) (DEVICE), Active rTMS (Bilateral LPC) (DEVICE), Placebo rTMS (Inactive) (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT03331796?

This trial is sponsored by Palo Alto Veterans Institute for Research, which has 50 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT03331796 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial